



Acute exercise tolerance among Veterans with Gulf War Illness

Jake Lindheimer, PhD

Deputy Associate Chief of Staff Office of Research and Development

William S. Middleton Veterans Memorial Hospital, Madison, WI

Jacob.Lindheimer@va.gov

This work was supported by Career Development Award #IK2CX001679 from the United States (U.S.) Department of Veterans Affairs Clinical Sciences Research and Development Service





The contents do not represent the views of the VA or the United States Government



Post-exertion malaise (PEM): a short-term condition where symptoms are exacerbated 24-48 hours following physical or cognitive stress

• Similar but more rapid responses to physical stress (<1 hour) are not PEM

Adverse event (AE): undesirable or harmful outcome that occurs during or after an intervention but is not necessarily caused by it

- "Serious" (e.g., death from heart attack) or "non-serious" (e.g., fatigue)
 - Examples of non-serious AE's include PEM and other similar effects
 - National exercise testing and prescription guidelines provide strategies for minimizing serious AE's, but what about non-serious AE's?

Rationale: what do prior studies tell us about minimizing non-serious AE's when prescribing exercise?



- CMI's have an elevated risk for non-serious AE's following exercise:

 - \uparrow sensitivity to experimental pain
 - \downarrow performance of cognitive tests
- Exercise challenge: physical stress → provoke symptoms → pathophysiology
- Informative for pathophysiology and risk awareness, but not always reflective of prescriptions used in exercise rehabilitation programs
- Lack of acute studies which compare risk of non-serious AE's across different exercise prescriptions makes guidance challenging

Specific aims and hypotheses



<u>Aim(s)</u>: Examine dose-response relationship between exercise-intensity and:

Psychometric outcomes: Symptoms, pain sensitivity, & cognitive performance (Aim 1) **Biological outcomes:** Inflammatory cytokines (Aim 2) **Behavioral outcomes:** Physical activity (Aim 3)

<u>Central hypothesis</u>: Relative to lower intensity exercise, higher intensity leads to larger:

- ↑ symptom severity (Aim 1a)
- ↑ sensitivity to experimental pain stimuli (Aim 1b)
- \checkmark cognitive performance (Aim 1c)
- ↑ inflammatory cytokines (Aim 2)
- \checkmark physical activity (Aim 3)











Results

Characteristics of final sample (n=40)



Characteristics	Frequency
Male/Female	90/10
White/Black/Multiple Races	95/2.5/2.5
Kansas Fatigue	90%
Kansas Pain	87.5%
Kansas Neuro/Cognitive/Mood	100%
Kansas Gastrointestinal	42.5%
Kansas Respiratory	32.5%
Kansas Dermatological	22.5%

GWI severity (Mean, SD)



Success of exercise dosing





Note. Data represented as means (95% CI)

Note. Data averaged across 20-min exercise phase





Primary results for Aims 1 & 3

Aim 1: Psychometric outcomes





Aim 3: Moderate-to-vigorous physical activity





Note. Data represented as means (95% CI)





Exploratory results

Basing exercise prescriptions solely on group level analyses may have limited application for certain individuals





Fatigue symptoms were elevated in the natural setting

Fatigue



40-A. Rest **B.** Light C. Moderate **D. Vigorous** 35-Symptom severity (0-100) 30-25-20-15-10-5 0 So' 1 0 · 50 20 20 200 2 min \sim \mathcal{Q}^{v} 20 6 2 5 200 \hat{o} 6, Q' ,hhi \mathcal{O} 0.min 0000 6000 ु 'nn' 'min 40, ⁷76 50 11 in





Discussion





<u>Scientific take home message</u>: On average, aerobic exercise intensities ≤ 75% max HR did not lead to greater risk of non-serious AEs

<u>Clinical take home message</u>: Regular moderate-to-vigorous physical activity (≤ 75% max HR) should be encouraged as part of the overall wellness plan for Veterans with GWI, especially those with milder symptom profiles.¹

<u>Veteran take home message</u>: Exercise is relatively safe and can improve your health and well-being. If you do experience pain and fatigue, exercising at lower intensities could reduce the risk of making your symptoms worse and can still provide some health benefits

¹ Exercise prescriptions should still take non-GWI related contraindications and risks into consideration ¹⁷

Limitations and future directions



Limitations

- 1. Unblinded study
- 2. Short-term effects
- 3. Generalizability

Future directions

- 1. Replication
- 2. Closer monitoring of nonserious adverse events
- 3. Risk stratification models

Acknowledgements



Thank you to the VISN-12 Veterans for their study participation and service!

Mentoring team Dr. Dane B. Cook Dr. Michael J. Falvo Dr. Christina Kendziorski Dr. Christopher Coe Dr. Monika Fleshner Dr. Andrew Alexander Study team

Alex Boruch Ellen Barhorst Tessa Rayne Gunnar Roberge

Sailor Brukardt

Zoie Leitel

Additional support

Dr. Karen Block VA New Jersey WRIISC Madison VA R&D Office Dr. James Lickel UW-Madison Kinesiology Dr. Safdar Lab

This work was supported by Career Development Award #IK2CX001679 from the United States (U.S.) Department of Veterans Affairs Clinical Sciences Research and Development Service